Silica nanoparticles as advanced platforms for nucleic acid delivery

Area of Science:

• Biomaterials Science
• Nanotechnology
• Gene Therapy

Background:

• Nucleic acid therapeutics (siRNA, mRNA, DNA, CRISPR/Cas) show promise but face delivery hurdles like instability and immune response.
• Current carriers (lipid, polymeric) lack resilience for complex nucleic acid payloads.
• Silica nanoparticles offer mechanical rigidity, tunable porosity, and versatile surface chemistry for nucleic acid delivery.

Purpose of the Study:

• To review how silica nanoparticle designs address limitations in nucleic acid delivery.
• To analyze strategies for overcoming systemic and intracellular barriers.
• To highlight silica platforms for next-generation gene therapy.

Main Methods:

• Problem-driven analysis of nanoarchitectural designs and surface functionalizations.
• Review of ligand-mediated targeting strategies for enhanced delivery.
• Focus on overcoming premature degradation, immune recognition, and endosomal escape.

Main Results:

• Silica nanoparticles provide robust encapsulation, protection, and controlled release of nucleic acids.
• Specific designs and functionalizations mitigate systemic instability and immune activation.
• Hybrid and biomimetic silica platforms enable theranostic functionalities and complex payloads.

Conclusions:

• Silica nanocarriers offer a promising platform for safe and efficient nucleic acid delivery.
• Their structural durability and chemical adaptability address key translational barriers.
• Silica architectures pave the way for advanced, clinically relevant gene therapies.